Although the world has returned to a state of relative normalcy, SARS-CoV-2 infections continue to persist worldwide, and immune evasive variants continue to emerge. Monoclonal antibodies (mAbs) are often first in line therapy for SARS-CoV-2 infections, but most have lost utility against the Omicron variant and its subvariants. One mAb cocktail, Evusheld,...

­Vaccines are an essential tool in preventing and controlling many diseases. Most approved vaccines are inactivated or live attenuated type, however, alternative platforms like mRNA and virus-like particles (VLPs) are being increasingly explored and approved because they generate potent immune responses with great safety profiles. VLPs are particularly...